Sofinnova Partners — Seed & Series A VC Firm ($500K–$15.0M Checks)
Sofinnova Partners is a Seed, Series A venture capital firm based in Paris, France (US office: San Francisco, CA) investing in Healthcare. The firm typically writes $500K–$15.0M checks and has 280 portfolio companies in our records.
- Check size
- $500K–$15.0M
- Portfolio
- 280 companies on record
- Partners
- 11 listed
- AUM
- $4.4B
- Stage
- Seed, Series A
- Sectors
- Healthcare
- HQ
- Paris, France (US office: San Francisco, CA)
Last verified: 2026-07-18
Seed, Series A
$500K – $15.0M
$4.4B
280+ companies
11 partners
About Sofinnova Partners
Sofinnova Partners is a venture capital firm headquartered in Paris, France, with a US office in San Francisco, California. The firm invests in early-stage companies focused on therapeutic innovation, particularly in biotech and immuno-oncology.
Sofinnova Partners participates in seed and series A financings. The firm typically deploys between $500K and $15.0M per investment. With $4.4B in assets under management, Sofinnova Partners maintains a focus on the healthcare and oncology sectors. Warm introductions are preferred when approaching the firm.
Investment Thesis
Sofinnova invests in early-stage companies in therapeutic innovation, particularly biotech and immuno-oncology.
How Sofinnova Partners invests
Sofinnova Partners is a vc firm based in Paris, France (US office: San Francisco, CA). The firm invests at the Seed, Series A stages, with a focus on Healthcare.
Sofinnova Partners typically writes checks of $500K–$15.0M per investment, backed by approximately $4.4B in assets under management.
Sofinnova Partners has backed 280 companies in our records, including Corvidia Therapeutics, Orchard Therapeutics, Advanced Perfusion Diagnostics.
Partners & Team
Industry Focus
Invests In
Recent Activity
Sofinnova Partners promotes Javier Nunez-Vicandi to Partner, strengthening its Digital Medicine strategy
Nov 2026 · Sofinnova Partners
Sofinnova Partners raises €650m for early-stage biotechs
Oct 2026 · pharmaphorum
Sofinnova Partners closes oversubscribed €82 million Sofinnova MD Start IV fund to create the next generation of medtech companies
Sep 2026 · Sofinnova Partners
Sofinnova Partners appoints David Evans as Partner
Jul 2026 · Sofinnova Partners
Sofinnova Partners announces Myricx Bio agrees to be acquired by Novartis
Jul 2026 · Sofinnova Partners
Investment Track Record
Sofinnova Partners has recorded investments in 282 portfolio companies. The firm has backed a range of therapeutic innovation companies including AAVantgarde Bio, ABIONYX Pharma, Abivax, Ablynx NV, Actithera, Addex Therapeutics, Advanced Perfusion Diagnostics, Afyren, Alia Therapeutics, Amolyt Pharma, Artios Pharma, Arzeda, Ascendis Pharma, Asceneuron, and Avantium.
These recorded investments reflect the firm's stated thesis of supporting early-stage companies in healthcare and oncology through seed and series A stages.
Portfolio Companies (280)
Other
Corvidia Therapeutics
Orchard Therapeutics
Advanced Perfusion Diagnostics
AAVantgarde Bio
ABIONYX Pharma
Abivax
Ablynx NV
Actithera
Addex Therapeutics
Afyren
- •Raising at Seed, Series A? You're squarely in their sweet spot.
- •Lead with your fit in Healthcare — the sectors they actively back.
- •Size your ask to their typical $500K – $15.0M check.
- •warm intro preferred
- •Address your outreach to a specific partner, such as Bommy Lee, Director of Communications.
- •A warm introduction beats a cold email. Get matched and request an intro.
Featured In
Browse More Investors
Fundraising resources
Frequently Asked Questions
See if Sofinnova Partners is a match for your startup
Upload your pitch deck to see how well you match with Sofinnova Partners and 10,000+ other investors.
Ask your AI assistant about this investor: connect InvestorMatch to Claude or ChatGPT
Is this your profile? Request a correction or removal